Global Uterine Cancer Drug Market - Industry Trends and Forecast to 2030

TABLE OF CONTENTS

1 INTRODUCTION 47

• 1.1 OBJECTIVES OF THE STUDY 47
• 1.2 MARKET DEFINITION 47
• 1.3 OVERVIEW OF THE GLOBAL UTERINE CANCER DRUGS MARKET 47
• 1.4 LIMITATIONS 49
• 1.5 MARKETS COVERED 49

2 MARKET SEGMENTATION 52

• 2.1 MARKETS COVERED 52
• 2.2 GEOGRAPHICAL SCOPE 53
• 2.3 YEARS CONSIDERED FOR THE STUDY 54
• 2.4 CURRENCY AND PRICING 54
• 2.5 DBMR TRIPOD DATA VALIDATION MODEL 55
• 2.6 MULTIVARIATE MODELLING 58
• 2.7 CANCER TYPE LIFELINE CURVE 58
• 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 59
• 2.9 DBMR MARKET POSITION GRID 60
• 2.10 MARKET END USER COVERAGE GRID 61
• 2.11 VENDOR SHARE ANALYSIS 62
• 2.12 SECONDARY SOURCES 63
• 2.13 ASSUMPTIONS 63

3 EXECUTIVE SUMMARY 64

4 PREMIUM INSIGHTS 67

• 4.1 PESTEL'S MODEL 70
• 4.2 PORTER'S 5 FORCES 71
• 4.3 EPIDEMIOLOGY 72

5 GLOBAL UTERINE CANCER DRUGS MARKET, REGULATORY FRAMEWORK 73

• 5.1 OVERVIEW 73
• 5.2 REGULATION IN THE U.S. 74
• 5.3 REGULATION IN CANADA 74
• 5.4 REGULATION IN EUROPE 74
• 5.5 REGULATION IN CHINA 74
• 5.6 REGULATION IN JAPAN 74
• 5.7 REGULATION IN AUSTRALIA 75
• 5.8 REGULATION IN INDIA 75
• 5.9 REGULATION IN BRAZIL 75
• 5.10 REGULATION IN SOUTH AFRICA 75

6 MARKET OVERVIEW 76

• 6.1 DRIVERS 78
  • 6.1.1 RISING INCIDENCE OF UTERINE CANCER WORLDWIDE 78
  • 6.1.2 GROWING ADVANCEMENTS IN TARGETED THERAPY FOR UTERINE CANCER 79
  • 6.1.3 RISING AWARENESS OF UTERINE CANCER 80
  • 6.1.4 RISING COLLABORATIONS AND PARTNERSHIPS AMONG LEADING PLAYERS 81
• 6.2 RESTRAINTS 82
  • 6.2.1 HIGH COST OF UTERINE CANCER TREATMENT 82
  • 6.2.2 SIDE EFFECTS AND TOXICITY ASSOCIATED WITH CANCER DRUGS 83
• 6.3 OPPORTUNITIES 84
  • 6.3.1 ADVANCEMENTS IN GENOMIC PROFILING AND BIOMARKER DISCOVERY 84
  • 6.3.2 GROWING R&D ACTIVITIES FOR UTERINE CANCER TREATMENT 85
• 6.4 CHALLENGES 86
  • 6.4.1 REGULATORY HURDLES IN THE UTERINE CANCER DRUGS MARKET 86
  • 6.4.2 DRUG RESISTANCE IN THE TREATMENT OF UTERINE CANCER 87

7 GLOBAL UTERINE CANCER DRUGS MARKET, BY CANCER TYPE 89

• 7.1 OVERVIEW 90
• 7.2 ENDOMETRIAL CANCER 93
  • 7.2.1 UTERINE CARCINOSARCOMA 94
  • 7.2.2 SEROUS ADENOSARCOMA 94
  • 7.2.3 ADENOSQUAMOUS CARCINOMA 94
  • 7.2.4 OTHER 94
• 7.3 UTERINE SARCOMA 95
  • 7.3.1 UTERINE LEIOMYOSARCOMA 95
  • 7.3.2 ENDOMETRIAL STROMAL SARCOMAS 95
  • 7.3.3 UNDIFFERENTIATED SARCOMA 96

8 GLOBAL UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE 97

• 8.1 OVERVIEW 98
• 8.2 CHEMOTHERAPY 101
  • 8.2.1 PACLITAXEL 102
  • 8.2.2 CARBOPLATIN 102
  • 8.2.3 CISPLATIN 102
  • 8.2.4 DOXORUBICIN 102
  • 8.2.5 DOCETAXEL 102
  • 8.2.6 OTHERS 102
• 8.3 IMMUNOTHERAPY 103

• 8.4 HORMONE THERAPY 103
  • 8.4.1 PROGESTINS 104
    • 8.4.1.1 MEDROXYPROGESTERONE ACETATE 104
    • 8.4.1.2 OTHERS 104
  • 8.4.2 AROMATASE INHIBITORS 105
    • 8.4.2.1 LETRAZOLE 105
    • 8.4.2.2 ANASTRAZOLE 105
    • 8.4.2.3 EXEMESTANE 105
  • 8.4.3 LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS 106
    • 8.4.3.1 GOSERELIN 106
    • 8.4.3.2 LEUPROLIDE 106
  • 8.4.4 OTHERS 106
• 8.5 TARGETED THERAPY 107
  • 8.5.1 LENVATINAB 107
  • 8.5.2 BEVACIZUMAB 107
  • 8.5.3 MTOR INHIBITORS 107
    • 8.5.3.1 EVEROLIMUS 108
    • 8.5.3.2 TEMSIROLIMUS 108
• 8.6 OTHERS 108

9 GLOBAL UTERINE CANCER DRUGS MARKET, BY DRUG TYPE 109

• 9.1 OVERVIEW 110
• 9.2 GENERICS 113
• 9.3 BRANDED 113
  • 9.3.1 KEYTRUDA 114
  • 9.3.2 LENVIMA 114
  • 9.3.3 PROVERA 115
  • 9.3.4 TEMODAR 115
  • 9.3.5 JEMPERLI 115
  • 9.3.6 OTHERS 115

10 GLOBAL UTERINE CANCER DRUGS MARKET, BY AGE GROUP 116

• 10.1 OVERVIEW 117
• 10.2 GERIATRIC 120
• 10.3 ADULTS 120

11 GLOBAL UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION 121

• 11.1 OVERVIEW 122
• 11.2 PARENTERAL 125
• 11.3 ORAL 125

12 GLOBAL UTERINE CANCER DRUGS MARKET, BY END USER 126

• 12.1 OVERVIEW 127
• 12.2 HOSPITALS 130
  • 12.2.1 PRIVATE 130
  • 12.2.2 PUBLIC 130
• 12.3 CANCER CENTERS 131
• 12.4 SPECIALTY CLINICS 131
• 12.5 OTHERS 132

13 GLOBAL UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL 133

• 13.1 OVERVIEW 134
• 13.2 DIRECT TENDER 137
• 13.3 RETAIL SALES 137
  • 13.3.1 HOSPITAL PHARMACY 138
  • 13.3.2 RETAIL PHARMACY 138
  • 13.3.3 ONLINE PHARMACY 138
• 13.4 OTHERS 139

14 GLOBAL UTERINE CANCER DRUGS MARKET, BY REGION 140

• 14.1 OVERVIEW 141
• 14.2 NORTH AMERICA 145
  • 14.2.1 U.S. 151
  • 14.2.2 CANADA 156
  • 14.2.3 MEXICO 161
• 14.3 EUROPE 166
  • 14.3.1 GERMANY 172
  • 14.3.2 U.K. 177
  • 14.3.3 FRANCE 182
  • 14.3.4 RUSSIA 187
  • 14.3.5 ITALY 192
  • 14.3.6 SPAIN 197
  • 14.3.7 TURKEY 202
  • 14.3.8 BELGIUM 207
  • 14.3.9 NETHERLANDS 212
  • 14.3.10 SWITZERLAND 217
  • 14.3.11 REST OF EUROPE 222

• 14.4 ASIA-PACIFIC 223
  • 14.4.1 CHINA 229
  • 14.4.2 JAPAN 234
  • 14.4.3 INDIA 239
  • 14.4.4 AUSTRALIA 244
  • 14.4.5 SOUTH KOREA 249
  • 14.4.6 NEW ZEALAND 254
  • 14.4.7 SINGAPORE 259
  • 14.4.8 THAILAND 264
  • 14.4.9 MALAYSIA 269
  • 14.4.10 INDONESIA 274
  • 14.4.11 PHILIPPINES 279
  • 14.4.12 REST OF ASIA-PACIFIC 284
• 14.5 SOUTH AMERICA 285
  • 14.5.1 BRAZIL 291
  • 14.5.2 ARGENTINA 296
  • 14.5.3 REST OF SOUTH AMERICA 301
• 14.6 MIDDLE EAST AND AFRICA 302
  • 14.6.1 SAUDI ARABIA 308
  • 14.6.2 U.A.E. 313
  • 14.6.3 SOUTH AFRICA 318
  • 14.6.4 EGYPT 323
  • 14.6.5 KUWAIT 328
  • 14.6.6 REST OF MIDDLE EAST AFRICA 333

15 GLOBAL UTERINE CANCER DRUGS MARKET, COMPANY LANDSCAPE 334

• 15.1 COMPANY SHARE ANALYSIS: GLOBAL 334
• 15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 335
• 15.3 COMPANY SHARE ANALYSIS: EUROPE 336
• 15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 337

16 SWOT ANALYSIS 338

17 COMPANY PROFILES 339

• 17.1 MERCK & CO., INC. 339
  • 17.1.1 COMPANY SNAPSHOT 339
  • 17.1.2 REVENUE ANALYSIS 339
  • 17.1.3 COMPANY SHARE ANALYSIS 340
  • 17.1.4 PRODUCT PORTFOLIO 340
  • 17.1.5 RECENT DEVELOPMENT 341

• 17.2 EISAI CO., LTD. 342
  • 17.2.1 COMPANY SNAPSHOT 342
  • 17.2.2 REVENUE ANALYSIS 342
  • 17.2.3 COMPANY SHARE ANALYSIS 343
  • 17.2.4 PRODUCT PORTFOLIO 343
  • 17.2.5 RECENT DEVELOPMENT 343
  • 17.2.6 RECENT DEVELOPMENT 344
• 17.3 SANOFI 345
  • 17.3.1 COMPANY SNAPSHOT 345
  • 17.3.2 REVENUE ANALYSIS 345
  • 17.3.3 COMPANY SHARE ANALYSIS 346
  • 17.3.4 PRODUCT PORTFOLIO 346
  • 17.3.5 RECENT DEVELOPMENT 347
• 17.4 PFIZER INC. 348
  • 17.4.1 COMPANY SNAPSHOT 348
  • 17.4.2 REVENUE ANALYSIS 348
  • 17.4.3 COMPANY SHARE ANALYSIS 349
  • 17.4.4 PRODUCT PORTFOLIO 349
  • 17.4.5 RECENT DEVELOPMENT 351
• 17.5 TEVA PHARMACEUTICALS USA, INC. 352
  • 17.5.1 COMPANY SNAPSHOT 352
  • 17.5.2 REVENUE ANALYSIS 352
  • 17.5.3 PRODUCT PORTFOLIO 353
  • 17.5.4 RECENT DEVELOPMENT 353
• 17.6 ACCORD HEALTHCARE US. 354
  • 17.6.1 COMPANY SNAPSHOT 354
  • 17.6.2 PRODUCT PORTFOLIO 354
  • 17.6.3 RECENT DEVELOPMENT 354
• 17.7 AMNEAL PHARMACEUTICALS LLC 355
  • 17.7.1 COMPANY SNAPSHOT 355
  • 17.7.2 REVENUE ANALYSIS 355
  • 17.7.3 PRODUCT PORTFOLIO 356
  • 17.7.4 RECENT DEVELOPMENT 356
• 17.8 BAXTER 357
  • 17.8.1 COMPANY SNAPSHOT 357
  • 17.8.2 REVENUE ANALYSIS 357
  • 17.8.3 COMPANY SHARE ANALYSIS 358
  • 17.8.4 PRODUCT PORTFOLIO 358
  • 17.8.5 RECENT DEVELOPMENT 358

• 17.9 ELI LILLY AND COMPANY 359
  • 17.9.1 COMPANY SNAPSHOT 359
  • 17.9.2 REVENUE ANALYSIS 360
  • 17.9.3 PRODUCT PORTFOLIO 360
  • 17.9.4 RECENT DEVELOPMENT 361
• 17.10 GETWELL ONCOLOGY 362
  • 17.10.1 COMPANY SNAPSHOT 362
  • 17.10.2 PRODUCT PORTFOLIO 362
  • 17.10.3 RECENT DEVELOPMENT 365
• 17.11 GSK PLC. 366
  • 17.11.1 COMPANY SNAPSHOT 366
  • 17.11.2 REVENUE ANALYSIS 366
  • 17.11.3 PRODUCT PORTFOLIO 367
  • 17.11.4 RECENT DEVELOPMENT 367
• 17.12 HIKMA PHARMACEUTICALS PLC 368
  • 17.12.1 COMPANY SNAPSHOT 368
  • 17.12.2 REVENUE ANALYSIS 368
  • 17.12.3 PRODUCT PORTFOLIO 369
  • 17.12.4 RECENT DEVELOPMENT 369
• 17.13 SUN PHARMACEUTICAL INDUSTRIES LTD. 370
  • 17.13.1 COMPANY SNAPSHOT 370
  • 17.13.2 REVENUE ANALYSIS 370
  • 17.13.3 PRODUCT PORTFOLIO 371
  • 17.13.4 RECENT DEVELOPMENT 371
• 17.14 VIATRIS INC. 372
  • 17.14.1 COMPANY SNAPSHOT 372
  • 17.14.2 REVENUE ANALYSIS 372
  • 17.14.3 PRODUCT PORTFOLIO 373
  • 17.14.4 RECENT DEVELOPMENT 373
• 17.15 VIRTUS 374
  • 17.15.1 COMPANY SNAPSHOT 374
  • 17.15.2 PRODUCT PORTFOLIO 374
  • 17.15.3 RECENT DEVELOPMENT 374

18 QUESTIONNAIRE 375

19 RELATED REPORTS 379

• 17.15 VIRTUS 374
  • 17.15.1 COMPANY SNAPSHOT 374
  • 17.15.2 PRODUCT PORTFOLIO 374
  • 17.15.3 RECENT DEVELOPMENT 374

18 QUESTIONNAIRE 375

19 RELATED REPORTS 379

LIST OF FIGURES

• FIGURE 1 GLOBAL UTERINE CANCER DRUGS MARKET: SEGMENTATION 52
• FIGURE 2 GLOBAL UTERINE CANCER DRUGS MARKET: DATA TRIANGULATION 55
• FIGURE 3 GLOBAL UTERINE CANCER DRUGS MARKET: DROC ANALYSIS 56
• FIGURE 4 GLOBAL UTERINE CANCER DRUGS MARKET : GLOBAL VS REGIONAL MARKET ANALYSIS 57
• FIGURE 5 GLOBAL UTERINE CANCER DRUGS MARKET: COMPANY RESEARCH ANALYSIS 57
• FIGURE 6 GLOBAL UTERINE CANCER DRUGS MARKET: INTERVIEW DEMOGRAPHICS 59
• FIGURE 7 GLOBAL UTERINE CANCER DRUGS MARKET: DBMR MARKET POSITION GRID 60
• FIGURE 8 GLOBAL UTERINE CANCER DRUGS MARKET: MARKET END USER COVERAGE GRID 61
• FIGURE 9 GLOBAL UTERINE CANCER DRUGS MARKET: VENDOR SHARE ANALYSIS 62
• FIGURE 10 GLOBAL UTERINE CANCER DRUGS MARKET: SEGMENTATION 66
• FIGURE 11 RISING INCIDENCE OF UTERINE CANCER IS EXPECTED TO DRIVE THE GROWTH OF THE GLOBAL UTERINE CANCER DRUGS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030 67
• FIGURE 12 ENDOMETRIAL CANCER SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL UTERINE CANCER DRUGS MARKET IN THE FORECAST PERIOD OF 2023 AND 2030 67
• FIGURE 13 NORTH AMEIRCA IS EXPECTED TO DOMINATE THE GLOBAL UTERINE CANCER DRUGS MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2023 TO 2030 68
• FIGURE 14 NORTH AMERICA IS THE FASTEST-GROWING MARKET FOR UTERINE CANCER DRUG MANUFACTURERS IN THE FORECAST PERIOD OF 2023 TO 2030 69
• FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL UTERINE CANCER DRUGS MARKET 77
• FIGURE 16 GLOBAL UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, 2022 90
• FIGURE 17 GLOBAL UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, 2023-2030 (USD THOUSAND) 91
• FIGURE 18 GLOBAL UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, CAGR (2023-2030) 91
• FIGURE 19 GLOBAL UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, LIFELINE CURVE 92
• FIGURE 20 GLOBAL UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, 2022 98
• FIGURE 21 GLOBAL UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, 2023-2030 (USD THOUSAND) 99
• FIGURE 22 GLOBAL UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, CAGR (2023-2030) 99
• FIGURE 23 GLOBAL UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, LIFELINE CURVE 100
• FIGURE 24 GLOBAL UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, 2022 110
• FIGURE 25 GLOBAL UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, 2023-2030 (USD THOUSAND) 111
• FIGURE 26 GLOBAL UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, CAGR (2023-2030) 111
• FIGURE 27 GLOBAL UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, LIFELINE CURVE 112
• FIGURE 28 GLOBAL UTERINE CANCER DRUGS MARKET: BY TYPE, 2022 117
• FIGURE 29 GLOBAL UTERINE CANCER DRUGS MARKET: BY AGE GROUP, 2023-2030 (USD THOUSAND) 118
• FIGURE 30 GLOBAL UTERINE CANCER DRUGS MARKET: BY AGE GROUP, CAGR (2023-2030) 118
• FIGURE 31 GLOBAL UTERINE CANCER DRUGS MARKET: BY AGE GROUP, LIFELINE CURVE 119
• FIGURE 32 GLOBAL UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2022 122
• FIGURE 33 GLOBAL UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND) 123
• FIGURE 34 GLOBAL UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030) 123
• FIGURE 35 GLOBAL UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 124
• FIGURE 36 GLOBAL UTERINE CANCER DRUGS MARKET: BY END USER, 2022 127
• FIGURE 37 GLOBAL UTERINE CANCER DRUGS MARKET: BY END USER, 2023-2030 (USD THOUSAND) 128
• FIGURE 38 GLOBAL UTERINE CANCER DRUGS MARKET: BY END USER, CAGR (2023-2030) 128
• FIGURE 39 GLOBAL UTERINE CANCER DRUGS MARKET: BY END USER, LIFELINE CURVE 129
• FIGURE 40 GLOBAL UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022 134
• FIGURE 41 GLOBAL UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 135
• FIGURE 42 GLOBAL UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 135
• FIGURE 43 GLOBAL UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 136
• FIGURE 44 GLOBAL UTERINE CANCER DRUGS MARKET: SNAPSHOT (2022) 142
• FIGURE 45 GLOBAL UTERINE CANCER DRUGS MARKET: COMPANY SHARE 2022 (%) 334
• FIGURE 46 NORTH AMERICA UTERINE CANCER DRUGS MARKET: COMPANY SHARE 2022 (%) 335
• FIGURE 47 EUROPE UTERINE CANCER DRUGS MARKET: COMPANY SHARE 2022 (%) 336
• FIGURE 48 ASIA-PACIFIC UTERINE CANCER DRUGS MARKET: COMPANY SHARE 2022 (%) 337